Healwell's 7% Quarter: The Plumbing Won, the AI Is Still Waiting
A drug-pricing shock shoved Healwell from episodic Canadian life-science work toward global health-system software. The revenue mix is moving. The P&L isn't — yet.
AIDX.TO · Earnings Call · 2026-11-10
The quarter that didn't look like the story
Healwell AI reported Q3 2026 revenue from continuing operations of $32.6 million, up 7% year over year. That is the headline. It is also, on its face, anemic for a company that grew 38% over the first nine months and spent two years telling investors it was a healthcare-AI compounder. Nine-month Data Science and AI revenue actually fell 13% to $6.1 million — the segment that carries the entire AI narrative. Strip out the divested Mutuo business and it grew about 2%. What did grow was the boring part. Healthcare Software revenue rose 44% to $92.6 million, essentially all of it the Orion Health acquisition, with subscription, support and maintenance up 47% to $64.8 million and now 70% of the total. Adjusted EBITDA more than doubled to $1.6 million, operating cash flow swung positive by $26 million versus the prior year, and total operating expenses fell 7%. Gross margin slipped to 52% from 54% — management's own explanation is that implementation work is being priced thin to win the recurring tail. So the real story is not the 7%. It is that Healwell is in the middle of changing what it sells, and the arithmetic of that change is currently working against the income statement while working for the cash flow statement.MFN as the accelerant nobody planned for
On the call, CEO James Lee framed the shift as deliberate — and then conceded it had been overtaken by policy: “we set out deliberately this year to diversify away from episodic life science revenue that was concentrated in Canada towards higher-margin global enterprise contracts. And that strategy was before MFN.” — James Lee, Chief Executive Officer · 2026-11-10 Most Favored Nation drug pricing, in his telling, is pushing new medicines out of Canada — at least 16 not launched in 2026, more than 30 delayed — so Canadian life-science budgets are thinning. Healwell's answer is to sell health information exchange infrastructure and clinical AI to health systems instead. That shows up all over this quarter's keyword set: global enterprise contracts is a fresh entry, as is software carriage network and the HIE Unlock construct that bundles the Orion HIE estate with the SMART Suite. SMART Summary is now shipping inside Intrahealth's EMR in New Brunswick and into Converge Health Iowa, whose 115-hospital exchange management says is worth north of $1 million a year once fully live. And what quietly left the stage matters as much. A year ago the number-one keyword on this company's calls was disease state — the 105-condition DARWEN screening pitch. This quarter "disease" is the single largest decliner in the company's keyword history. Management still cites 57 peer-reviewed publications and a cardiology study finding 4,100 untreated heart-failure patients, but the commercial emphasis has moved from finding patients to owning the rails patients sit on. The company has swapped an AI-diagnostics story for a health-IT plumbing story. That pivot is not idiosyncratic. On the global tape, the durable advancers in care-delivery themes are payor-adjacent — gaps in care has been among the strongest multi-month movers, carried by UNH, CNC and HUM. Finding under-treated patients is a real budget line. Healwell's problem is that it is currently monetizing the infrastructure needed to find them, not the finding itself.Revenue recognition: the excuse that keeps recurring
The tension in this call is not the strategy. It is the timing, and the fact that the timing explanation has now appeared in three consecutive reports. In November 2025, Lee promised investors that the proof-of-value count would be disclosed: “there's well north of 5. But you'll see us talk about those numbers in early 2026.” — James Lee, Chief Executive Officer · 2025-11-07 That disclosure never arrived; this quarter the vocabulary shifted from proof of value to proof point, with WELLTRUST consent — over 100,000 patients, mid-40% consent rates — offered as the substitute. In August 2026, CFO Anthony Lam guided AI and Data Science toward roughly $13 million for the full year, at the low end of a 30–50% range. Nine months in, that segment has booked $6.1 million. In August, Lee said “what's giving us confidence in the second half is revenue recognition is effectively the key issue there.” — James Lee, Chief Executive Officer · 2026-08-07 On Tuesday he said it again, this time about the margin target:That is a conditional 10% exit margin, not a reiterated one — and it lands after a quarter in which the analyst community was already testing whether the target needed cutting. Meanwhile the growth algorithm itself has been quietly reset: Lam told the call the business now targets “a 10% growth rate on an annual basis” — Anthony Lam, Chief Financial Officer · 2026-11-10, a phrase that would have been unrecognizable on a call twelve months ago.the reality is we've won most of the cost. So how we get to recognize that revenue by hitting key milestones in this quarter will be whether or not we can hit 10%.